KRAS and neoplasm: We also investigated whether BLT2 inhibition could suppress tumor formation and IL-6 production in these mice and observed that treatment with LY255283 clearly suppressed KRAS-driven lung tumor formation (Fig. 3g–j) and IL-6 production (Fig. 3k).